Is there a relationship between interleukin-6 (rS1800795) polymorphism and human papillomavirus?
DOI:
https://doi.org/10.21527/2176-7114.2025.50.15641Keywords:
Inflammation, Interleukin-6, Human papillomavirus, PolymorphismAbstract
Objective: To assess the relationship between interleukin-6 (IL-6) polymorphism and the human papillomavirus (HPV) infection among women in a capital city in Northeastern Brazil. Methods: This cross-sectional study included sexually active women who received care through the public health system in São Luís, Maranhão State, Brazil. Information was collected on sociodemographic characteristics, sexual health, and number of pregnancies. Cytopathological analysis was performed using the Papanicolaou stain. HPV was detected using a nested polymerase chain reaction (PCR), and IL-6 −174G>C (rs1800795) polymorphism was detected by real-time PCR. For analysis of relationships with epidemiological and clinical data, patients were divided into two groups according to HPV status (HPV DNA-positive and -negative), and differences were deemed significant at p < 0.05. Results: The sample comprised 195 participants, 68 (34.88%) of whom were positive for HPV DNA. The prevalence of IL-6 −174G>C polymorphism was 28.72%, with 26.67% of patients exhibiting heterozygosity (GC) and 2.05% homozygosity (CC), indicating Hardy–Weinberg equilibrium. Conclusion: There was no association between IL6 −174G>C polymorphism and HPV status in the analyzed population. The findings of this study do not support the association between HPV DNA positivity and IL-6 −174G>C polymorphism among sexually active women in São Luís, Brazil.
References
1Akbari E, Milani A, Seyedinkhorasani M, Bolhassani A. HPV co-infections with other pathogens in cancer development: a comprehensive review. J Med Virol. 2023;95:e29236.
2Viveros-Carreño D, Fernandes A, Pareja R. Updates on cervical cancer prevention. Int J Gynecol Cancer. 2023;33(3):394-402.
3Brasil. Estudo Epidemiológico sobre a Prevalência Nacional de Infecção pelo HPV (POP-BRASIL) - 2015-2017 / Associação Hospitalar Moinhos de Vento. Porto Alegre, 2020. 89 p.
4Cohen PA, Jhingran A, Oaknin A, Denny L. Câncer cervical. Lancet. 2019;393(10167):169-182.
5Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021;6:263.
6Cai C, Peng X, Zhang Y. Serum IL-6 level predicts the prognosis and diagnosis in cervical cancer patients. Int J Women's Health. 2022;14:655-663.
7Vitkauskaite A, Celiesiute J, Juseviciute V, Jariene K, Skrodeniene E, Samuolyte G, Nadisauskiene RJ, Vaitkiene D. IL-6 597A/G (rs1800797) and 174G/C (rs1800795) Gene Polymorphisms in the Development of Cervical Cancer in Lithuanian Women. Medicina. 2021;57:1025.
8Hirano T. IL-6 in inflammation, autoimmunity and câncer. 2021;33(3):127–148.
9Li X, Zhang X, Wang Y, Li J, Guo Y, Zhao L, et al. The cervicovaginal expression level of interleukin-6 can be a prediction factor for cervical intraepithelial neoplasias and cervical cancer: a prospective cohort study. Clin. Exp. Obstet. Gynecol. 2023;50(11):239.
10Bonin-Jacob CM, Almeida-Lugo LZ, Puga MAM, Machado AP, Padovani CTJ, Noceti MC, et al. L-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus. Plos One. 2021;16(3):e0248639.
11Shaswati M, Oeishy FH, Mumu SB, Zahid MZI, Hossain M, Haque MA, et al. Polymorphism of the interleukin-6 (IL-6) gene contribute to cervical câncer susceptibility in Bangladeshi women: a case-control study. Health Sci Rep. 2023:6e1238.
12Harun-Or-Roshid M, Ali MB, Jesmin, Mollah MNH. Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk. Plos one. 2021;16(3):e0247055.
13Pourroostaei Ardakani P, Abkhiz S, Sheykhi K, Adhami Mojarad K, Rahimi B, Panahi M, Hooshmand M. Molecular Investigation of the Association Among Common Interleukin-6 Polymorphism and Human Papillomavirus Genotypes with Cervical Cancer Among Iranian Women. Monoclon Antib Immunodiagn Immunother. 2023;42(4):125-131.
14Prema A, Kalarani I, Veerabathiran R. Genetic predisposition of interleukin-6 (rs1800797) polymorphism in cervical cancer: A Meta-analysis. Biomedical Research and Therapy. 2024;11(3):6268-6275.
15Porto CR, De Oliveira Kleine JP, Longatto Filho A, Da Silva ID. Polymorphism of Interleukin-6 is not associated with the presence or absence of high HPV E6/E7. Anticancer Res. 2014;34(7):3501-4.
16Instituto Nacional de Câncer José Alencar Gomes da Silva. Diretrizes brasileiras para o rastreamento do câncer do colo do útero. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. 2. ed. rev. atual. Rio de Janeiro: INCA, 2016.
17Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol. 2002;40(3):902–7.
18Ministério Ministério da Saúde (BR); Conselho Nacional de Saúde. Resolução nº 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos e revoga as Resoluções CNS nos. 196/96, 303/2000 e 404/2008. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:549.
19Cunha APA, Belfort IKP, Mendes FPB, Santos GRB, Costa LHL, Monteiro PM, et al., Human papillomavirus and its association with other sexually transmitted coinfection among sexually active women from the northeast of Brazil. Interdiscip Perspect Infect Dis. 2020; 29:e8838317
20Ross RJ, Marinelli N, Vidal FCB, Fraga EC, Nascimento MDSB, Safadi MAP. Frequency of human papilomavirus and associated factors in gypsy and quilombola women. BMC Women's Health. 2023; 23:160.
21Wagh P, Kulkarni P, Kerkar S, Tongaonkar H, Chaudhari H, Warke H, et al. Polymorphism of interleukin-6 -174 G/C (rs1800795) & the corresponding interleukin-6 level as a prognostic marker of cervical cancer. Indian J Med Res. 2021;154(2):391-398.
22Albosale AH, Mashkina EV. Association between promoter polymorphisms of IL-1B, IL-4 and IL-6 genes and a viral load infected women with human papillomavirus. J Reprod Infertil. 2021;22(2)92-102.
23 Fernandes AP, Gonçalves MA, Simões RT, Mendes-Junior CT, Duarte G, Donadi EA. A pilot case-control association study of cytokine polymorphisms in Brazilian women presenting with HPV-related cervical lesions. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):241-4.
24Marangon AV, Guelsin GA, Visentainer JE, Borelli SD, Watanabe MA, Consolaro ME, et al. The association of the immune response genes to human papillomavirus-related cervical disease in a Brazilian population. Biomed Res Int. 2013;2013:146079.
25Lima Júnior SF, Tavares MM, Macedo JL, Oliveira RS, Heráclio SA, Maia MM, et al. Influence of IL-6, IL-8, and TGF-β1 gene polymorphisms on the risk of human papillomavirus-infection in women from Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2016;111:663-669.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Context and Health Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
